Lung Cancer

Emily Curran, MD

Principal Investigator

AML/ALL

Phase 1

Protocol BAML-16-001

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Leeya Pinder, MD, PhD

Cancer Screening & Prevention

Protocol LMI-001-A-S04

Self Collection HPV Screening Study

This study compares self-collected vaginal HPV tests to clinician-collected cervical tests in adults referred for colposcopy after abnormal screening. It checks how well self-collection detects high-risk HPV and cervical precancer, and asks about ease of use and preferences. Outcomes are measured from one visit with lab results within 60 days.

Alberto Martini, MD

Genitourinary Cancer

Phase 3

Protocol 78278343PCR3001 (KLK2-ComPAS)

Pasritamig for Advanced Prostate Cancer

A phase 3 randomized trial testing pasritamig, a T cell redirecting drug, plus best supportive care versus placebo plus best supportive care in people with metastatic prostate cancer that no longer responds to hormones. The main goal is to see if pasritamig improves overall survival. The study also tracks disease progression, pain, quality of life, and safety over about 2 years and 8 months.

Bailey Nelson

Genitourinary Cancer

Phase 2

Protocol S2427

Bladder Preservation Immunoradiation

This Phase II study gives pembrolizumab with external beam radiation to patients whose muscle invasive bladder cancer has responded to pre-surgery chemotherapy. The goal is to see if this approach preserves the bladder and achieves at least 70% bladder intact event-free survival at 3 years, while tracking side effects and quality of life over up to 5 years.

Alberto Martini, MD

Urology | Genitourinary Cancer

Phase 2

Protocol ABLE-22 (000434)

Study on New Bladder Cancer Treatment Options

This study explores new treatment options for high-grade non-muscle invasive bladder cancer using a drug called nadofaragene firadenovec. Participants receive this treatment alone or combined with chemotherapy or immunotherapy to measure its effectiveness in reducing cancer recurrence.

Alberto Martini, MD

Urology | Genitourinary Cancer

Phase 3

Protocol ABLE-32 (000423)

Trial of Nadofaragene Firadenovec vs. Observation for Bladder Cancer

The study compares a new treatment called Nadofaragene Firadenovec with regular observation in people who have a specific type of bladder cancer. The key focus is on preventing the cancer from returning or getting worse.

Emily Curran, MD

AML/ALL

Protocol EA9181

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL

This clinical trial, conducted by the National Cancer Institute, is testing treatments for adults newly diagnosed with BCR-ABL-positive acute lymphoblastic leukemia. It compares the effects of standard chemotherapy and steroids with a tyrosine kinase inhibitor (TKI) to the same regimen plus blinatumomab, a drug that may help stop cancer cell growth. The study aims to determine if the combination therapy improves overall survival and reduces residual disease. It also assesses the side effects and outcomes for patients who undergo different treatment paths. The trial is currently recruiting. Participants must be 18 to 75 years old and meet specific health criteria.

Alberto Martini, MD

Urology | Genitourinary Cancer

Phase 2

Protocol MVR-T3011-006

Study on Herpes Virus Injection for Bladder Cancer Treatment

This clinical study is testing a Herpes Virus injection for bladder cancer that hasn't responded to standard treatments. The study seeks to determine if this new treatment is safe and effective by administering two different dosages. Researchers aim to see improvements in patient outcomes over visits spanning up to two years.

Alberto Martini, MD

Urology | Genitourinary Cancer

Phase 2

Protocol CORE-008

Cretostimogene in High Risk NMIBC

This Phase 2 trial tests cretostimogene given into the bladder for people with high risk non muscle invasive bladder cancer. It includes groups who are BCG naive, previously treated with BCG, or BCG unresponsive. One group also tests adding gemcitabine. Main goals are tumor response, time free of high grade events, and safety. Treatment begins with 6 weekly doses and continues with scheduled maintenance and long term checks.

Alberto Martini, MD

Urology | Genitourinary Cancer

Phase 2

Protocol QUILT-2.005

Study of BCG and ALT-803 for Non-Muscle Invasive Bladder Cancer

This study compares a combination of BCG and ALT-803 treatments against BCG alone for non-muscle invasive bladder cancer to see which works better at preventing cancer progression over time.

Caroline Billingsley, MD

Gynecologic Cancer

Phase 1

Protocol ACR-368-201

Phase 2 Study of ACR-368 in Endometrial Cancer

This open-label Phase 2 trial studies ACR-368 alone or with ultra-low dose gemcitabine in people with high-grade endometrial cancer. Patients are grouped by a predictive test when available. The study measures tumor response every 8 weeks and monitors safety and survival for up to 2 years.

Trisha Wise-Draper, MD, PhD

Phase 1 - Solid Tumor | Skin Cancer & Sarcoma

Phase 1

Protocol IDE196-001

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor | Gastrointestinal Cancer

Protocol 10579

ZEN003694 with Capecitabine for Advanced Solid Tumors

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment.

Chris Lemmon, MD

Lung Cancer

Phase 3

Protocol MK-1084-004

Study of MK-1084 and Pembrolizumab for Lung Cancer

This study explores the combination of MK-1084 and pembrolizumab for treating a specific type of lung cancer. It checks if this duo is better than current options by increasing survival rates and slowing cancer progression.

Adam Rojan, MD

Gastrointestinal Cancer

Protocol NRG-GI008

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 3

Protocol 22615 SOHO-02

Study on BAY 2927088 for Lung Cancer with HER2 Mutations

This study tests BAY 2927088 for treating advanced lung cancer with HER2 mutations, comparing it to current treatments. It focuses on safety and effectiveness through various health checks and scans over up to four years.

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Phase 2

Protocol GO44479

Efficacy and Safety of Adjuvant in Patients With Resected Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

Trisha Wise-Draper, MD, PhD

Phase 1 - Solid Tumor | Skin Cancer & Sarcoma

Phase 1

Protocol GIM531-CT01

Study of GIM-531 for Advanced Solid Tumors

This study is testing a new drug called GIM-531 for people with advanced solid tumors. They want to know if it's safe and works well, especially for those who haven't responded to other treatments. Participants must have advanced cancer and cannot have certain medical conditions.

Ed Faber, MD

Myeloma

Phase 2

Protocol LPS18183

Study of Isatuximab, Carfilzomib, and Dexamethasone for Multiple Myeloma

This study looks at a new treatment combination for people with multiple myeloma not responding to previous treatments. Using isatuximab, carfilzomib, and dexamethasone, it aims to find out if this combo is effective and how it affects patients.

Mahmoud Charif, MD

Breast Cancer

Phase 3

Protocol A012301

Low-Dose Tamoxifen for Early-Stage Breast Cancer Study

This research compares a low dose of tamoxifen with standard hormone therapies to treat early-stage breast cancer in post-menopausal women, checking if it's as effective in preventing recurrence.

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor | Gastrointestinal Cancer

Protocol 10522

Pancreatic Ductal- Met or unrectable

Gemcitabine/ Nab-Paclitaxel + CA-4948, must have had prior 5FU based therapy

Robert Franklin, MD

Genitourinary Cancer

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body.

Ed Faber, MD

Lymphoma | CLL | Other

Phase 1

Protocol P-CD19CD20-ALLO1-001

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

This clinical trial, sponsored by Poseida Therapeutics, is an open-label, Phase 1 study evaluating the safety of P-CD19CD20-ALLO1 CAR-T cells in adults with certain relapsed or refractory B cell malignancies. The study involves dose escalation to find a safe dosage and examines the treatment's safety and effectiveness over time. Participants will undergo lymphodepletion therapy before receiving the CAR-T cells. The trial aims to measure safety, adverse events, and responses to treatment, including survival rates and progression-free survival.

Ian Paquette, MD

Gastrointestinal Cancer

Protocol CCTG-CO32

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?

Trisha Wise-Draper, MD, PhD

Phase 1 - Solid Tumor

Phase 1

Protocol PYX-201-101

Safety and Effectiveness of PYX-201 in Solid Tumors

This study is testing PYX-201, a new drug for patients with advanced solid tumors that didn't respond to traditional treatments. Researchers want to determine the safest dose while checking for any side effects.

Chris Lemmon, MD

Lung Cancer

Phase 3

Protocol V940-009

Pembrolizumab Study for Non-Small Cell Lung Cancer Treatment

This study is examining if adding the drug V940 to pembrolizumab helps prevent non-small cell lung cancer from returning after surgery. Participants must meet specific health criteria and cannot have certain prior treatments or conditions. The research will assess various health outcomes like survival and quality of life over a period that could last up to about 129 months.

Jordan Kharofa, MD

Gastrointestinal Cancer

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer.

Sara Medek, MD

Head and Neck Cancer

Phase 3

Protocol NANORAY-312

Investigating NBTXR3 and Radiation for Head and Neck Cancer

This study looks at how effective a new treatment, NBTXR3 combined with radiation therapy, is compared to standard treatment for elderly patients with advanced head and neck cancer who cannot have chemotherapy.

Thomas Herzog, MD

Gynecologic Cancer

Phase 3

Protocol MK-2870-022/GOG-3103

Study on New Treatment for Recurrent Ovarian Cancer

This study tests a new drug for ovarian cancer that has returned. It compares the new treatment's safety and effectiveness with standard care to see if patients live longer without their disease getting worse. Patients will be closely monitored for side effects.

Thomas Herzog, MD

Gynecologic Cancer

Phase 3

Protocol GOG-3107 (PRO1184-002/GCT1184-02)

Testing Rina-S Effectiveness for Platinum-Resistant Ovarian Cancer

This study tests whether Rina-S works better than standard chemotherapy against ovarian cancer that's resistant to platinum treatments. Participants get either Rina-S or a standard therapy, with all receiving active treatment-no placebo. The goal is to see if it helps patients live longer without their cancer getting worse.

Chris Lemmon, MD

Head and Neck Cancer

Phase 2

Protocol BNT113-01

Trial of BNT113 and Pembrolizumab for HPV16+ Head and Neck Cancer

This study looks into a new treatment approach using BNT113 and pembrolizumab for head and neck cancer linked to HPV16. Patients' safety, response rates, and overall survival will be compared between those getting the combined treatment versus standard pembrolizumab treatment alone.

Zulfa Omer, MD

Lymphoma | CLL

Protocol NX-5948-301

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Jamie Lewis, MD

Breast Cancer

Protocol NRG-CC015

Exploring Mindfulness Apps for Breast Cancer Survivors

This study investigates if digital mindfulness methods help younger women who survived breast cancer manage depression. It compares a live online program to a self-paced app to find the best solution for improving mental health.

Ed Faber, MD

Myeloma

Phase 3

Protocol EMN30/64007957MMY3003

Teclistamab Maintenance Study

A Phase 3 randomized trial testing whether teclistamab, alone or with lenalidomide, is a better maintenance treatment after transplant than lenalidomide alone in people with newly diagnosed multiple myeloma. Main goals are longer time without disease worsening and more patients having no detectable disease at 12 months.

Zulfa Omer, MD

Other

Phase 1

Protocol M23-647

Evaluating Safety and Efficacy of ABBV-101 for B-Cell Malignancies

The study evaluates a new drug, ABBV-101, for adults with certain B-cell cancers. It examines safety, effectiveness, and the movement of ABBV-101 through the body over about five years. Participants will have regular hospital visits for monitoring and tests.

Robert Franklin, MD

Phase 1 - Solid Tumor | Genitourinary Cancer

Phase 1

Protocol LOXO-FG3-22001

Study on LOXO-435 for Treating FGFR3-Altered Cancers

This study is looking at how effective and safe LOXO-435 is for treating specific advanced cancers. Participants will have cancers with a particular gene change (FGFR3) and will be observed over about 2.5 years.

Chris Lemmon, MD

Lung Cancer

Phase 2

Protocol 61186372NSC2012 COPERNICUS

Study on Treatment Combinations for Advanced Lung Cancer

This study is testing how well certain drug combinations work against advanced lung cancer with specific genetic mutations. Two different combinations are being tested: one is a mix of two drugs, amivantamab and lazertinib, and the other is amivantamab with chemotherapy. The study hopes to control cancer growth and improve survival.

Lalanthica Yogendran, MD

Brain Cancer

Phase 3

Protocol IVY-P3-24-021

Comparing Niraparib and Temozolomide for Newly-diagnosed Glioblastoma

This study compares two drugs, Niraparib and Temozolomide, to see which is better at treating newly-diagnosed glioblastoma, a type of brain tumor. Participants receive one of the drugs along with radiation. The study measures effectiveness in stopping cancer progression and improving survival.

Robert Franklin, MD

Genitourinary Cancer

Phase 3

Protocol A032103

Blood Test for ctDNA in Guiding Immunotherapy After Bladder Cancer Surgery

This study is testing if a blood test that checks for DNA from bladder cancer cells can guide the use of immunotherapy after surgery. It aims to find out if this approach can help prevent the cancer from coming back. The study will involve patients who have had bladder cancer surgery and will look at how well additional treatments work based on the blood test results.

Tahir Latif, MD

Lymphoma | Blood Cancer

Phase 1

Protocol LYL314-101

Study of IMPT-314 in R/R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.

Kerri McGovern, MD

Lung Cancer

Phase 3

Protocol ResQ201A-NSCLC

Testing a New Combination Therapy for Advanced Lung Cancer

The trial compares a new therapy involving N-803 and tislelizumab with standard treatment for advanced lung cancer. It's aimed at patients whose cancer did not respond well to previous immune-based treatments. Enrolled participants will be watched over a year to determine which treatment better increases survival rates.

Robert Franklin, MD

Genitourinary Cancer

Protocol S1931

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic).

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor

Phase 1

Protocol YL211-INT-101-01

Safety Study of YL211 for Advanced Solid Tumors

This study investigates a new drug, YL211, to assess its safety and effectiveness in treating patients with advanced solid tumors. The goal is to determine optimal dosing and observe any side effects over about three years.

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor

Phase 1

Protocol C5421001

Study of PF-07934040 for Advanced Tumors with KRAS Gene Mutations

This study tests a new cancer drug, PF-07934040, for people with advanced tumors having KRAS mutations. Participants will take this drug alone or with other therapies to see its safety and effectiveness. The study lasts up to four years, with regular clinic visits.

Ed Faber, MD

Myeloma

Phase 3

Protocol M22-574

Comparing ABBV-383 to Standard Treatments in Relapsed Multiple Myeloma

This study will compare a new medicine, ABBV-383, to current treatments for people with relapsed multiple myeloma, aiming to provide better management and outcomes for the disease.

Emily Curran, MD

AML/ALL | Blood Cancer

Protocol ETCTN 10596

Adding SNDX-5613 to the Standard Chemotherapy Treatment for Newly Diagnosed Patients With Acute Myeloid Leukemia

This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene.

Tahir Latif, MD

Lymphoma

Phase 2

Protocol ALLO-501A-202

Testing New Treatment for Residual Cancer in B-cell Lymphoma Patients

This study tests a new treatment called cema-cel for adults with large B-cell lymphoma who show minimal residual disease after initial therapy. It aims to compare this treatment's effectiveness and safety against standard observation post-treatment.

Trisha Wise-Draper, MD, PhD

Head and Neck Cancer

Protocol 10492

Study of Ipatasertib with Chemoradiation for Head and Neck Cancer

This study investigates whether adding ipatasertib to standard chemo-radiation improves treatment outcomes for head and neck cancer. The goal is to find a safe dose that might offer better cancer control than existing therapies alone.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 3

Protocol NVL-655-04

Neladalkib vs Alectinib in ALK NSCLC

This Phase 3 trial enrolls people with untreated ALK-positive advanced non-small cell lung cancer. It compares neladalkib (NVL-655) with alectinib to see which drug better delays cancer progression. About 450 patients will be randomized and followed for up to five years for cancer outcomes, brain effects, safety, and quality of life.

Chris Lemmon, MD

Head and Neck Cancer

Phase 3

Protocol MCLA-158-CL02

Study on Petosemtamab for Treated Head and Neck Cancer

This study tests Petosemtamab versus other treatments chosen by doctors on previously treated head and neck cancer patients. Its goal is to see if Petosemtamab improves outcomes for these patients.

Amanda Jackson, MD

Gynecologic Cancer

Phase 3

Protocol MK-2870-020/GOG-3101

Study Compares Treatments for Recurrent or Metastatic Cervical Cancer

The study tests a new drug, sacituzumab tirumotecan, against standard treatments for cervical cancer that has returned or spread. It aims to learn whether this new drug can help patients live longer. Participants must have tried previous treatments but still have growing cancer. Some medical conditions will exclude participation.

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Protocol 10608

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable).

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor | Gastrointestinal Cancer

Phase 1

Protocol ETCTN 10670

Testing Abemaciclib with 5-Fluorouracil for Metastatic Colorectal Cancer

This study tests a new combination of cancer drugs for people with advanced colorectal cancer that hasn't responded to other treatments. It aims to find a safe dose that can be tolerated by most patients while seeing if the drug combo is effective in treating the cancer.

Amanda Jackson, MD

Gynecologic Cancer

Protocol NRG-CC008

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations. Participants will choose to undergo surgery to remove the fallopian tubes only and plan to have the ovaries removed in the future (BLS group) or remove the fallopian tubes and ovaries at the same time (BSO group).

Trisha Wise-Draper, MD, PhD

Phase 1 - Solid Tumor | Skin Cancer & Sarcoma | Lung Cancer | Genitourinary Cancer

Phase 1

Protocol DB-1311-O-1001

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 3

Protocol PRESERVE-003

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy.

Zulfa Omer, MD

CLL

Phase 1

Protocol ZE50-0134-0002

Study of ZE50-0134 for Chronic Lymphocytic Leukemia and Lymphomas

This study tests ZE50-0134 in adults with certain blood cancers like chronic lymphocytic leukemia that have not responded to standard treatments. Researchers aim to find a safe dose level and evaluate effectiveness over several weeks through different stages of testing. Participants should not have certain serious health conditions.

Ed Faber, MD

Myeloma

Phase 3

Protocol 64007957MMY3005

Study on Teclistamab and Talquetamab for Treating Multiple Myeloma

This study tests new medication combos, teclistamab and talquetamab, for treating newly diagnosed multiple myeloma patients who can't have a stem cell transplant yet. It compares their effectiveness against current standard treatments over several years.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 1

Protocol ETCTN 10629

Combining Iadademstat with Immunotherapy for Advanced Lung Cancer

Researchers are studying whether adding a new drug, iadademstat, to existing immunotherapies can better control small cell lung cancer. The study involves repeated cycles of treatment and aims to find out if this combination can keep the cancer stable longer than current treatments alone.

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor

Phase 1

Protocol J5J-OX-JZZA

Testing LY3962673 in KRAS G12D-Mutant Solid Tumors

This study examines the safety and effectiveness of the drug LY3962673 for treating cancers with the KRAS G12D mutation. This includes certain types of pancreatic, lung, and colon cancers. The study will explore how well the drug works alone and alongside other treatments over a period of five years.

Zulfa Omer, MD

Lymphoma | CLL

Phase 1

Protocol UB-VV111-01

Study on UB-VV111 and Rapamycin for CD19+ B-cell Malignancies

This study tests a new treatment, UB-VV111, with or without Rapamycin in patients with certain returning B-cell cancers. It evaluates the safety and how well the treatment works over two years. Eligible participants must meet specific health criteria. Pregnant women and people with certain conditions cannot join.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 3

Protocol CA224-1093

Comparing Treatments for Advanced Non-small Cell Lung Cancer

This study compares two drug combinations for treating advanced lung cancer. It aims to see which treatment helps patients live longer and whether they can manage side effects.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 2

Protocol IOV-LUN-202

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

Trisha Wise-Draper, MD, PhD

Head and Neck Cancer

Phase 2

Protocol BCA101X301

Study of Ficerafusp Alfa and Pembrolizumab for Head and Neck Cancer

This clinical trial is testing a new drug combination, ficerafusp alfa and pembrolizumab, to treat certain head and neck cancers. Participants will either receive the new combination or a placebo, and researchers aim to assess its safety and effectiveness over several years.

Chad Zender, MD

Head and Neck Cancer | Skin Cancer & Sarcoma

Phase 3

Protocol NRG-HN014

Study of Cemiplimab and Surgery for Advanced Skin Cancer

This study evaluates whether adding the immunotherapy drug cemiplimab to surgery improves treatment outcomes for patients with advanced, resectable skin cancer.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 2

Protocol BNT327-06

Study of BNT327 and Chemotherapy for Lung Cancer Treatment

This study is testing a new drug called BNT327 with chemotherapy in adults with a type of lung cancer known as non-small cell lung cancer. It's looking at whether this treatment combo can help patients live longer and experience fewer tumor growths. The study involves regular visits over a period of up to 5 years.

Trisha Wise-Draper, MD, PhD

Phase 1 - Solid Tumor | Skin Cancer & Sarcoma | Lung Cancer

Phase 1

Protocol IOV-GM1-201

Study on IOV-4001 for Advanced Melanoma and NSCLC

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Amanda Jackson, MD

Phase 1 - Solid Tumor

Phase 1

Protocol SGR-3515-101

Testing a New Drug SGR-3515 for Advanced Solid Tumors

This study tests a new drug, SGR-3515, for people with advanced solid tumors. It checks its safety, how well it's tolerated, and its potential effectiveness. Participants need to have a specific health profile and not have certain other conditions or recent treatments.

Andrew Frankart, MD

Head and Neck Cancer | Gynecologic Cancer | Genitourinary Cancer | Gastrointestinal Cancer

Protocol UCCC-RT-23-01

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

Zulfa Omer, MD

Other

Protocol 10590

Comparing Effectiveness of Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).

Jordan Kharofa, MD

Gastrointestinal Cancer

Phase 3

Protocol NRG-GI011

Higher Dose Radiation Therapy for Advanced Pancreatic Cancer Trial

This study tests if higher doses of radiation therapy help people with advanced pancreatic cancer live longer after initial chemotherapy. It compares this treatment to regular care options like continued chemotherapy or observation and measures survival and quality of life impacts.

Trisha Wise-Draper, MD, PhD

Head and Neck Cancer

Protocol EA3132

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA SCC of the Head and Neck

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck and disruptive p53 mutations who have undergone surgery.

Timothy Struve, MD

Genitourinary Cancer

Phase 2

Protocol NRG-GU012

Testing Radiation Plus Immunotherapy for Metastatic Renal Cell Cancer

The study looks at whether adding stereotactic radiation to immunotherapy helps patients with advanced kidney cancer that can't be removed by surgery. The study aims to improve how well treatments work together against cancer progression.

Ed Faber, MD

Blood Cancer

Phase 1

Protocol NXC-201-AL-001

Study on NXC-201 CAR-T for Relapsed Light Chain Amyloidosis

This study tests a treatment known as NXC-201 CAR-T for patients with relapsed or hard-to-treat AL amyloidosis. It will check how safe and helpful the treatment is over a period of two years.

Zulfa Omer, MD

CLL

Phase 2

Protocol UCCC-HEM-23-01

Untreated Chronic Lymphocytic Leukemia

Venetoclax therapy with Acalabrutinib

Robert Franklin, MD

Genitourinary Cancer

Phase 1

Protocol PSMA-007-001

Study of JANX007 in Metastatic Castration-Resistant Prostate Cancer

This study is testing a new drug, JANX007, for treating advanced prostate cancer that has spread and is resistant to other treatments. It aims to determine the safety of the drug and how patients handle its side effects.

Timothy Struve, MD

Genitourinary Cancer

Phase 3

Protocol NRG-GU008

Testing the Addition of the Drug Apalutamide to Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery.

Chris Lemmon, MD

Head and Neck Cancer

Phase 3

Protocol 221530

Comparing Dostarlimab vs Placebo After Chemoradiation for Head and Neck Cancer

This study tests if Dostarlimab helps prevent cancer from returning or spreading in patients with advanced head and neck cancer after chemoradiation. Participants must be newly diagnosed without distant cancer spread. It lasts up to 5 years.

Ed Faber, MD

Blood Cancer | Myeloma

Phase 1

Protocol P-BCMA-ALLO1-001

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Lalanthica Yogendran, MD

Brain Cancer

Phase 2

Protocol A072201

New Treatments for Recurrent Glioblastoma

This study compares new drugs, relatlimab and nivolumab, with traditional chemotherapy for treating recurrent glioblastoma to see which is more effective and safer.

Kerri McGovern, MD

Breast Cancer

Phase 3

Protocol A012303

ShortStop HER2 Duration Study

This trial compares 6 months versus 12 months of HER2-targeted therapy (trastuzumab with or without pertuzumab) in people with early HER2-positive breast cancer who had no invasive cancer at surgery after pre-surgery chemo. It checks cancer recurrence, quality of life, side effects, and long-term outcomes with up to 10 years follow-up.

Kyle Wang, MD

Brain Cancer

Phase 3

Protocol NRG-BN013

Comparing Two Radiation Therapies for Brain Cancer Spread from Other Body Parts

This study examines whether a longer duration of radiation therapy (called FSRS) is better than the usual shorter therapy (SRS) for people with certain cancers that have spread to the brain. It involves comparing how well each method works in preventing cancer from growing and the side effects experienced.

Tahir Latif, MD

Lymphoma

Phase 2

Protocol EA4231

Testing a New Combo Therapy for Relapsed Aggressive B-cell Lymphoma

This study is testing a combination of 5 drugs-venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid-called ViPOR, to see if it is effective in treating patients with certain types of aggressive B-cell lymphoma that have come back or not responded to treatment.

Trisha Wise-Draper, MD, PhD

Lymphoma | Phase 1 - Solid Tumor | Myeloma

Phase 2

Protocol TAPUR

TAPUR Study: FDA Approved Drugs Targeting Tumor Gene Abnormalities

This study explores how FDA-approved drugs targeting specific tumor gene abnormalities affect patients with certain advanced cancers. Eligible participants should be 12 years and older and meet specific inclusion criteria.

Eric Vick, MD

Phase 1 - Hematologic Malignancies

Phase 1

Protocol AJX-101

Study of AJ1-11095 for Untreatable Myelofibrosis Patients

This study tests the safety and effectiveness of a new drug, AJ1-11095, on myelofibrosis patients who haven't responded to previous treatments. Participants will receive the drug to find out the safest dose.

Trisha Wise-Draper, MD, PhD

Head and Neck Cancer | Phase 1 - Solid Tumor

Phase 1

Protocol SRF114-101

Testing CHS-114 in People with Advanced Solid Tumors

This study is testing a new treatment, CHS-114, for people with difficult-to-treat solid tumors. It checks if the treatment is safe and helpful and looks at how patients respond. There are three parts: testing different doses of the treatment, saw about its effects alone, and combined with another drug.

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Protocol S2104

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

Tahir Latif, MD

Lymphoma

Phase 2

Protocol MK2140-011

DLBCL GCB Treatment Study

A phase 2 trial comparing zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP in people with newly diagnosed GCB subtype DLBCL. The main goal is to see which treatment gives more complete responses at the end of therapy and to compare safety and longer term outcomes.

Trisha Wise-Draper, MD, PhD

Head and Neck Cancer

Phase 4

Protocol CHS-007-01 / RTOG 3521

Study of Toripalimab With Chemotherapy for Nasopharyngeal Cancer

This study tests if a drug combo, including toripalimab, helps treat certain advanced nasopharyngeal cancers. Participants should not have had similar treatments before or foreign growths that are curable with other treatments. Researchers will assess benefits like tumor shrinkage.

Davendra Sohal, MD, MPH

Head and Neck Cancer | Phase 1 - Solid Tumor | Lung Cancer | Gastrointestinal Cancer

Phase 1

Protocol R7075-ONC-2009

Safety and Efficacy of REGN7075 and Cemiplimab in Cancer

This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage.

Chris Lemmon, MD

Head and Neck Cancer

Protocol NRG-HN010

Testing Ado-Trastuzumab Emtansine Compared to the Usual Treatment for Salivary Gland Cancer

This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable).

Trisha Wise-Draper, MD, PhD

Brain Cancer

Letrozole Study in Recurrent High Grade Gliomas

Gliomas- Letrozole+Standard Therapy

Sara Medek, MD

Head and Neck Cancer

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell)

Emily Curran, MD

AML/ALL

Phase 1

Protocol 10630

Testing New Drug Combo for Treating Acute Myeloid Leukemia

This study tests if a combination of three drugs can safely treat newly diagnosed AML patients. Researchers seek to find the safest dose and see how well this drug combo helps fight leukemia.

Amanda Jackson, MD

Gynecologic Cancer

Phase 2

Protocol FTH-PIK-201

Study of Sapanisertib and Serabelisib with Paclitaxel for Endometrial Cancer

This study tests a combination of drugs with a special diet in patients with advanced endometrial cancer. It seeks to find out if this new treatment improves patient outcomes and understand any side effects. To join, patients must have failed previous treatments like chemotherapy. Participants must fit specific criteria, including having certain genetic markers, and they should not have other major health issues.

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Phase 1

Protocol RMC-GI-102

Study of RAS Inhibitors in GI Tumors

This study evaluates new RAS inhibitors combined with standard or new treatments for patients with gastrointestinal cancers, including colorectal and pancreatic cancers. The focus is on safety, tolerability, and early antitumor effects. The study has three parts, each testing different drug combinations. Participants must be adults with certain cancer types and meet health criteria. Outcomes include monitoring adverse events, drug levels, and patient responses over time.

Chris Lemmon, MD

Head and Neck Cancer

Phase 3

Protocol AV-299-23-301

Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic HPV Negative Head and Neck SCC

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer.

Trisha Wise-Draper, MD, PhD

Gynecologic Cancer | Phase 1 - Solid Tumor | Lung Cancer

Phase 1

Protocol DB-1305-O-1001

Trial of DB-1305 for Advanced Solid Tumors

This study is testing a new drug called DB-1305 in people with advanced solid tumors to find the best dose and check for side effects. Participants must be adults whose tumors haven't responded to other treatments. They will need regular visits over treatment cycles.

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Phase 3

Protocol RMC-6236-302

Testing RMC-6236 for Metastatic Pancreatic Cancer Treatment

This Phase 3 study tests RMC-6236 against standard chemotherapy in patients with metastatic pancreatic cancer who have already received treatment. It aims to see if the new drug improves survival rates and delays disease progression. Participants need to be 18 years or older and meet certain health criteria.

Jennifer Leddon, MD, PhD

Lung Cancer

Phase 3

Protocol D702BC00001 ARTEMIDE-Lung02

Study of Rilvegostomig vs. Pembrolizumab with Chemotherapy for Lung Cancer

This study compares rilvegostomig against pembrolizumab when taken with chemotherapy for treating advanced squamous NSCLC in patients whose tumors express PD-L1.

Trisha Wise-Draper, MD, PhD

Phase 1 - Solid Tumor | Skin Cancer & Sarcoma

Phase 2

Protocol RPL-003-19

A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS)

This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients.

Caroline Billingsley, MD

Gynecologic Cancer

Phase 3

Protocol GOG-3068

Study on Heated Chemotherapy and Niraparib for Advanced Ovarian Cancer

This study investigates whether heated chemotherapy applied during surgery, followed by the drug niraparib, improves outcomes for patients with advanced ovarian, primary peritoneal, and fallopian tube cancers. Two groups will be compared: one receiving heated chemotherapy and the other not. All patients will receive standard chemotherapy and then niraparib after surgery.

Zulfa Omer, MD

Other

Protocol ETCTN 10637

Testing Venetoclax for Relapsed Hairy Cell Leukemia

This study examines whether venetoclax is effective in treating patients with relapsed hairy cell leukemia. It involves taking the medication daily and regular check-ups for up to 19 cycles.

Kerri McGovern, MD

Breast Cancer

Protocol A012103

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer

Pembro or Observation

Ed Faber, MD

Myeloma

Phase 1

Protocol M24-108

Study on ABBV-383 for Relapsed or Refractory Multiple Myeloma

This study tests ABBV-383, a drug for relapsed/refractory multiple myeloma, focusing on safety and side effects. About 180 people will participate globally, receiving the drug by IV every 28 days for up to three years, with regular check-ups.

Zulfa Omer, MD

Lymphoma | CLL | Other

Phase 1

Protocol NX-5948-301

NX5948 in Relapsed B Cell Cancer

This Phase 1 study tests NX-5948, an oral BTK degrader, in adults with relapsed or refractory B‑cell cancers. The study will find safe dose(s), track side effects and drug levels, and see if the drug can shrink or control these cancers across several disease groups.

Tahir Latif, MD

Myeloma

Protocol BB2121?EAP?001

Nonconforming idecabtagene vicleucel (CAR-T) Expanded Access Program

This program allows patients with multiple myeloma to receive their own batch of idecabtagene vicleucel that failed commercial release when remanufacturing is not possible. It monitors safety and effectiveness at qualified treatment centers and excludes patients with allergies or health issues that make treatment unsafe.

Emily Curran, MD

AML/ALL

Protocol A041501

Inotuzumab With Chemotherapy for Young Adults with Newly Diagnosed B-Cell ALL

This phase 3 trial tests whether adding the antibody drug inotuzumab ozogamicin to a pediatric-style chemotherapy plan is safe and helps young adults with newly diagnosed B-cell ALL stay in remission longer. Patients who respond to induction chemo are randomized to standard therapy with or without inotuzumab. The study follows patients for treatment effects, side effects, and long-term outcomes.

Zulfa Omer, MD

CLL

Phase 2

Protocol UCCC-HEM-24-01

CLL/SLL- Received 2nd G BTKi+/-Obinutuzu

Epcoritamab as consolidation therapy

Emily Curran, MD

AML/ALL

Phase 2

Protocol 21CTP.LEUK01

Phase II Trial of Asciminib, Prednisone, Blinatumomab, for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia

This phase II trial adds asciminib to dasatinib, prednisone, and blinatumomab for adults with newly diagnosed Ph+ CD19+ acute lymphoblastic leukemia. The study checks whether this combination improves deep molecular remission by about day 85 and monitors remission, survival, and side effects. Treatment includes induction, consolidation cycles, and long-term maintenance up to five years.

Chris Lemmon, MD

Head and Neck Cancer

Protocol TP-CA-006

HNSCC Longitudinal Multiomic Study

An observational study collecting tumor tissue and blood over time from adults with metastatic or unresectable head and neck squamous cell carcinoma starting first‑line anti‑PD‑1/PD‑L1 therapy. Tests will include NGS, ctDNA, RNA, and immune profiling to discover biomarkers linked to treatment response and resistance. Follow up is up to 5 years.

Emily Curran, MD

Phase 1

Protocol LP-118-US-I01

A Study of LP-118 in Patients With Advanced Tumors

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

Emily Curran, MD

AML/ALL

Phase 2

Protocol BAML-16-001-S21

Beat AML Biomarker Treatment Trial

This master trial screens AML patients with fast genomic and lab testing and assigns them to one of several targeted treatment sub-studies. The main goals are to show testing and assignment can be done within 7 days and to evaluate treatment response and safety over time.

Emily Curran, MD

AML/ALL

Phase 1

Protocol BAML-16-001-S24

Beat AML Biomarker Treatment Trial

This master trial screens AML patients with fast genomic and lab testing and assigns them to one of several targeted treatment sub-studies. The main goals are to show testing and assignment can be done within 7 days and to evaluate treatment response and safety over time.

Alberto Martini, MD

Urology | Genitourinary Cancer

Phase 3

Protocol UT002

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

This study tests how well a new drug, UGN-104, treats low-grade upper tract urothelial cancer. Participants receive weekly doses for 6 weeks, followed by possible monthly maintenance doses if they respond well. Participants are monitored for safety and effectiveness over about 15 months.

Robert Franklin, MD

Genitourinary Cancer

Phase 1

Protocol XmAb819-01

Study of XmAb819 in Advanced Clear Cell Kidney Cancer

This study is exploring the safety and proper dose of a new drug, XmAb819, for treating a type of kidney cancer that hasn't responded to other treatments. Participants will get the drug either by IV or injection and be closely monitored for side effects and changes in their cancer.

Trisha Wise-Draper, MD, PhD

Head and Neck Cancer

Phase 1

Protocol UCCC-HN-24-01

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Head and Neck Cancer

This trial tests short-course proton or photon radiation given with pembrolizumab before salvage surgery in recurrent head and neck squamous cell carcinoma. Phase I finds a safe radiation dose; Phase II compares the two radiation types to see if the combo increases major pathologic response. Patients are followed for safety and long-term outcomes up to 5 years.

Ed Faber, MD

Myeloma

Phase 3

Protocol KT-US-679-0788

Comparing Anitocabtagene Autoleucel to Standard Therapy for Relapsed/Refractory Multiple Myeloma

This study compares a new drug, anitocabtagene autoleucel, with standard treatments for multiple myeloma that has not responded to other treatments. Participants need to have tried 1-3 other treatments previously. The study aims to see if the new drug is better at stopping the disease from getting worse.

Jennifer Leddon, MD, PhD

Phase 1 - Solid Tumor

Phase 1

Protocol TV56278-ONC-10203

Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 alone or with Pembrolizumab

This study tests the safety and effectiveness of TEV-56278, alone and with Pembrolizumab, in treating advanced solid tumors. Participants will be involved for up to two years, receiving treatment and undergoing monitoring to assess drug safety and any anti-tumor activity.

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor

Phase 1

Protocol YL217-INT-101-01

First Test of Cancer Drug YL217 for Patients with Advanced olid Tumors

This study examines how a new cancer drug, YL217, works on patients with advanced solid tumors. Patients must be adults with measurable tumors and good health status. Researchers want to learn about the drug's safety and effectiveness.

Zulfa Omer, MD

CLL

Phase 2

Protocol NX-5948-201

A Study of NX-5948 in Adults With CLL/SLL Previously Treated

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.

Davendra Sohal, MD, MPH

Phase 1 - Solid Tumor

Phase 1

Protocol TTX-080-001

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080 monotherapy (HLA-G inhibitor) +/- pembrolizumab or cetuximab

Emily Curran, MD

AML/ALL

Phase 3

Protocol BAML-16-001-S25

Beat AML Biomarker Treatment Trial

This master trial screens AML patients with fast genomic and lab testing and assigns them to one of several targeted treatment sub-studies. The main goals are to show testing and assignment can be done within 7 days and to evaluate treatment response and safety over time.

Olugbenga Olowokure, MD

Gastrointestinal Cancer

Phase 3

Protocol S2433

Panitumumab for KRAS Wild Type Pancreas

This randomized phase III trial tests whether adding panitumumab to standard second line chemotherapy improves survival for adults with unresectable or metastatic KRAS wild type pancreatic cancer. Participants receive chemotherapy with or without panitumumab until progression or unacceptable side effects, with follow up for up to three years. The study also looks at tumor response, side effects, and quality of life.

Trisha Wise-Draper, MD, PhD

Head and Neck Cancer

Phase 2

Protocol NRG-CC013

Study on BMX-001 for Reducing Mouth Sores in Head and Neck Cancer Patients

This study explores if the drug BMX-001 can reduce painful mouth sores in patients undergoing chemoradiation therapy for head and neck cancer. By comparing it to a placebo, researchers aim to see if BMX-001 offers additional relief.

Zulfa Omer, MD

CLL

Phase 2

Protocol UCCC-HEM-24-02

A Multicenter Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated and T474 Gatekeeper Mutant CLL/SLL

This is a multicenter parallel two cohort, phase II clinical trial designed to evaluate the combination of obinutuzumab + LP-168 for the treatment of: 1) previously treated, and 2) BTK T474I ( gate keeper mutation) mutated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients.

Kyle Wang, MD

Radiation Oncology

Protocol 2024-0002

Heart Health Screening During Cancer Care

This study uses routine radiation planning CT scans to look for signs of heart artery calcium and help identify heart disease earlier in people receiving cancer radiation therapy.

Bailey Nelson

Radiation Oncology

Protocol 2016-1287

Learning About Radiation Treatment

This study tests whether a short educational video helps people better understand radiation treatment and the consent process.